Prime Gene Therapeutics
Privately held: no public share price
Assets
(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | JAK1/2Small molecule | Atopic Dermatitis |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
1 June 2026Filing acceptedpumecitinibChina NDA for pumecitinib gel in atopic dermatitis accepted by NMPA CDE (reported)
CN, NMPA (CDE) · Prime Gene Therapeutics (Beijing Puqi Medical) · Source ↗
Financial reports
No financial reports recorded.